A robust analytical characterization of adenoviral (AdV) vectors is a foundational component for de-risking therapeutic programs and ensuring a clear path toward Investigational Medicinal Product Dossier (IMPD) submissions. A detailed analytical package provides unambiguous data on vector identity, purity, and potency. This data directly informs preclinical study design and satisfies MHRA and other global regulatory expectations for Advanced Therapy Medicinal Products (ATMPs). This framework moves beyond simple vector quantification to build a deep, data-driven understanding of the asset’s key quality attributes.

Analytical Characterization of Adenoviral Vectors for ATMP Development

Proven Intelligence in Vector Analytics

The analytical strategy for an adenoviral vector program is a foundational component of its preclinical and clinical trajectory. The structural complexity and immunogenic potential of adenoviruses demand a multi-faceted characterization approach to generate the data required for successful regulatory submissions in the UK and globally.

A tailored analytical package provides the necessary evidence of product quality and consistency. Key domains of investigation include:

• Vector Identity and Genomic Integrity: Confirmation that the correct genetic payload is packaged within the intended capsid structure. This involves next-generation sequencing (NGS) of the vector genome and mass spectrometry to verify capsid protein composition.

• Purity and Impurity Profiling: Detailed quantification of process- and product-related impurities. This includes measuring residual host cell DNA and proteins, as well as characterizing the proportion of empty or aggregated particles that could impact efficacy or immunogenicity.

• Potency and Infectious Titer: Development of qualified, biologically relevant assays to measure the functional activity of the vector. This is a direct measure of the product’s ability to transduce target cells and express the therapeutic transgene.

Strategic Insights from Chimeric Vector Analysis

Developing novel adenoviral vectors often involves creating chimeric capsids to expand the available serotype repertoire and overcome pre-existing neutralizing antibodies in the patient population (PMID: 17197043). This engineering work necessitates a parallel evolution in analytical methods. A pre-defined analytical panel may not be suitable for a chimeric vector; instead, methods must be specifically adapted to recognize and quantify the modified capsid.

Detailed analytical work can determine which specific capsid components are the primary targets of neutralizing antibodies. Understanding the differential impact of anti-hexon versus anti-fiber antibodies on in vivo transduction provides direct, actionable intelligence for vector design and preclinical model selection (PMID: 15721355). This level of characterization helps predict vector performance and de-risks the transition into IND-enabling toxicology studies.

As one partner noted, our team possesses, “Vast knowledge in all aspects of vector production and analytics.” This expertise is applied within our >100,000 sq ft of specialized laboratory and preclinical facilities to build the robust data packages needed for global submissions. While Franklin Biolabs was formally launched in 2024, our core scientific team’s track record includes a 100% successful IND rate since 2019, demonstrating a history of execution that aligns analytical development with regulatory success.

This deep analytical foundation is a core component of our integrated services, which are detailed further in our Vector | CMC | Analytics Services overview.